Table 4.

Association between severe hematuria (≥21 RBCs/hpf) and eGFR during follow-up

	Average eGFR decline for hematuria ≥21 RBCs/hpf versus <21 RBCs/hpf
Adjusted for	eGFR decline (mL/min/1.73 m2)	95% Lower	95% Upper	P-value
Time	−1.3928	−7.9793	−2.5198	<0.001
Time + estimated proteinuria	−3.8229	−6.7408	−0.9049	0.010
Time + M	−5.2376	−7.9856	−2.4896	<0.001
Time + E	−5.0537	−7.6789	−2.4285	<0.001
Time + S	−5.0082	−7.6671	−2.3493	<0.001
Time + T	−5.2425	−8.0541	−2.4310	<0.001
Time + C	−5.2517	−7.9126	−2.5908	<0.001
Time + RASB	−5.2768	−8.0925	−2.4611	<0.001
Time + immunosuppression	−5.2773	−8.0307	−2.5239	<0.001
Time + RASB, immunosuppression	−5.2995	−8.1296	−2.4694	<0.001
Time + estimated proteinuria + T	−3.9867	−6.9359	−1.0375	0.008

n = 390 laboratory measures available between biopsy date and last follow-up or ESRD, among 72 patients.

Severe hematuria was categorized as severe (≥21) versus not severe (<21).

GEE models using time-dependent predictors were modeled as main effects, and time-independent predictors (MEST-C scores) were considered along with an interaction term for time in order to estimate a within-subjects effect.

P-values in bold denote significance at the 0.05 level.